Mechanisms of miRNAs and their expression in gastric cancer

Document Type : Original Articles

Authors

1 Department of Pathology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

2 Department of Pediatrics, School of Medicine, Amir al momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran

3 Department of anatomical sciences, Faculty of medicine, Zabol University of medical sciences, Zabol, Iran.

4 Department of Pathology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

5 Department of plant Breeding and Biotechnology, Faculty of Agriculture, University of Zabol, Zabol, Iran.

6 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran,

7 Department of Agronomy and Plant Breeding, Faculty of Agriculture and Natural Resources, University of Mohaghegh Ardabili, Ardabil, Iran.

8 Department of Agronomy and Plant Breeding, Agriculture Institute, Research Institute of Zabol, Zabol, Iran,

10.32592/ARI.2025.80.1.217

Abstract

Gastric cancer is the fourth most common cancer in the world and the second leading cause of cancer-related deaths worldwide. Gastric cancer was responsible for approximately 768,000 deaths. MicroRNAs (miRNAs), as short non-coding RNAs, undoubtedly play a central and decisive role in various types of cancer due to their interaction with target genes. Since the discovery of the identity and clinical functions of miRNAs in the past few decades, their potential as therapeutic targets in cancer research has been the focus of extensive study. The aim of this study is to investigate the role of microRNAs in gastric cancer, focusing on their expression, biogenesis, and potential as therapeutic biomarkers. MicroRNAs (miRNAs) are essential regulators of cell proliferation, signaling pathways, and the cell cycle. They can also serve as markers of metastasis in the stomach, liver, and lymph nodes, as well as indicators of response to chemotherapy in cancer patients. Several studies have shown that miRNAs in gastric cancer have been effective as biomarkers for cancer prognosis. Currently, various oncogenic clinical trials are underway, exploring the use of miRNAs in screening, diagnosis, and drug testing. However, many systematic molecular mechanisms, including a detailed investigation of miRNAs and their expression in gastric cancer, remain unknown. Therefore, in addition to presenting the updated results of recent preclinical studies, researchers have investigated the biogenesis of miRNAs and their expression in cancer cells. It is hoped that the analysis of molecular interaction effects and the identification of miRNA target molecules and signaling pathways will contribute to the prevention and treatment of this disease.

Keywords

Main Subjects

References

  1. Bae JH, Kang MJ, Yang KM, Kim TO, Yi JM. Epigenetically silenced microRNAs in gastric cancer: Functional analysis and identification of their target genes. Oncol Rep. 2015;34(2):1017-26.
  2. Debnath T, Deb Nath NC, Kim EK, Lee KG. Role of phytochemicals in the modulation of miRNA expression in cancer. Food Funct. 2017;8(10):3432-42.
  3. Irmak-Yazicioglu MB. Mechanisms of MicroRNA Deregulation and MicroRNA Targets in Gastric Cancer. Oncology research and treatment. 2016;39(3):136-9.
  4. Sado AI, Batool W, Ahmed A, Zafar S, Patel SK, Mohan A, et al. Role of microRNA in colorectal carcinoma (CRC): a narrative review. Annals of medicine and surgery (2012). 2024;86(1):308-18.
  5. Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, et al. Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discov. 2016;6(2):188-201.
  6. Hosseinahli N, Zeinali T, Hosseinahli N, Karimi L, Shanehbandi D, Mansoori B, et al. Restoration of miRNA-143 Expression Inhibits Growth and Migration of MKN-45 Gastric Cancer Cell Line. Adv Pharm Bull. 2022;12(1):183-90.
  7. Hou W, Zhao Y, Zhu H. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects. Int J Mol Sci. 2023;24(20).
  8. Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol. 2014;20(34):12007-17.
  9. Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432-9.
  10. Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, et al. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2015;778:46-51.
  11. Babaei M, Pourfarzi F, Yazdanbod A, Chiniforush MM, Derakhshan MH, Mousavi SM, et al. Gastric cancer in Ardabil, Iran--a review and update on cancer registry data. Asian Pacific journal of cancer prevention : APJCP. 2010;11(3):595-9.
  12. Vosoo K, Sarli A, Yousefi Y, Khavand S, Veisi F. Evaluation of the prevalent genotypes of human papillomavirus in the population of women in Golestan province in the northeastern of Iran. Cell Mol Biomed Rep. 2024;4(4):237-43.
  13. Yavuz B, Cil OC, Cayir A. Evaluation of circulating cell-free nucleic acids in plasma as biomarkers of laryngeal cancer. Cell Mol Biomed Rep. 2024;4(4):216-25.
  14. Elkhawaga SY, Ismail A, Elsakka EG, Doghish AS, Elkady MA, El-Mahdy HA. miRNAs as cornerstones in adipogenesis and obesity. Life Sciences. 2023;315:121382.
  15. Elkady MA, Doghish AS, Elshafei A, Elshafey MM. MicroRNA-567 inhibits cell proliferation and induces cell apoptosis in A549 NSCLC cells by regulating cyclin-dependent kinase 8. Saudi Journal of Biological Sciences. 2021;28(4):2581-90.
  16. Doghish AS, Elsisi AM, Amin AI, Abulsoud AI. Circulating miR-148a-5p and miR-21-5p as Novel Diagnostic Biomarkers in Adult Egyptian Male Patients With Metabolic Syndrome. Canadian Journal of Diabetes. 2021;45(7):614-8.
  17. Sasani S, Rashidi Monfared S, Mirzaei AR. Identification of some Echinophora platyloba miRNAs using computational methods and the effect of these miRNAs in the expression of TLN2 and ZNF521 genes in different human body organs. Cell Mol Biomed Rep. 2024;4(1):43-53.
  18. Liao Y, Gui Y, Li Q, An J, Wang D. The signaling pathways and targets of natural products from traditional Chinese medicine treating gastric cancer provide new candidate therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(6):188998.
  19. Reddy KTK, Reddy AS. Recent Breakthroughs in Drug Delivery Systems for Targeted Cancer Therapy: An Overview. Cellular, Molecular and Biomedical Reports. 2025;5(1):13-27.
  20. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic acids research. 2007;36(suppl_1):D154-D8.
  21. Griffiths-Jones S. miRBase:The MicroRNA Sequence Database. In: Ying S-Y, editor. MicroRNA Protocols. Totowa, NJ: Humana Press; 2006. p. 129-38.
  22. Yang Z, Ren F, Liu C, He S, Sun G, Gao Q, et al. dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genomics. 2010;11(4):S5.
  23. Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H, et al. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic acids research. 2017;45(D1):D812-D8.
  24. Lu Z, Shi X, Gong F, Li S, Wang Y, Ren Y, et al. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. Acta Pharmaceutica Sinica B. 2020;10(6):1004-19.
  25. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Molecular cell. 2003;11(6):1457-66.
  26. Wang Y, Gu X, Li Z, Xiang J, Jiang J, Chen Z. microRNA expression profiling in multidrug resistance of the 5Fuinduced SGC7901 human gastric cancer cell line. Molecular medicine reports. 2013;7(5):1506-10.
  27. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology. 2009;77(1):12-21.
  28. Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. British journal of cancer. 2012;107(8):1345-53.
  29. Wang Z, Liu J, Xie J, Yuan X, Wang B, Shen W, et al. Regulation of autophagy by non-coding RNAs in gastric cancer. Frontiers in oncology. 2022;12:947332.
  30. Pargol M, Karizi SZ, Akbari M, Nourmohammadi B, Shadmehr MB, Karimipoor M, et al. Investigation the role of autophagy in non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention: APJCP. 2021;22(3):947.
  31. Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2016;1859(1):169-76.
  32. Luo M, Tang J, Zhu Y, Wu L, Fu H, Zhang F, et al. MiRNA-219a-1-3p inhibits the malignant progression of gastric cancer and is regulated by DNA methylation. Oncologie. 2023;25(5):495-506.
  33. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews cancer. 2006;6(11):857-66.
  34. Tohidast M, Memari N, Amini M, Hosseini SS, Jebelli A, Doustvandi MA, et al. MiR-145 inhibits cell migration and increases paclitaxel chemosensitivity in prostate cancer cells. Iranian Journal of Basic Medical Sciences. 2023;26(11):1350.
  35. Nai A, Zeng H, Wu Q, He Z, Zeng S, Bashir S, et al. lncRNA/miR-29c-mediated high expression of LOX can influence the immune status and chemosensitivity and can forecast the poor prognosis of gastric cancer. Frontiers in Cell and Developmental Biology. 2022;9:760470.
Archives of Razi Institute
Volume 80, Issue 1
January and February 2025
Pages 217-224

Files

Share

How to cite

Statistics